Retinoic acid induced 1, RAI1: A dosage sensitive gene related to neurobehavioral alterations including autistic behavior

Paulina Carmona-Mora, Katherina Walz

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Genomic structural changes, such as gene Copy Number Variations (CNVs) are extremely abundant in the human genome. An enormous effort is currently ongoing to recognize and catalogue human CNVs and their associations with abnormal phenotypic outcomes. Recently, several reports related neuropsychiatric diseases (i.e. autism spectrum disorders, schizophrenia, mental retardation, behavioral problems, epilepsy) with specific CNV. Moreover, for some conditions, both the deletion and duplication of the same genomic segment are related to the phenotype. Syndromes associated with CNVs (microdeletion and microduplication) have long been known to display specific neurobehavioral traits. It is important to note that not every gene is susceptible to gene dosage changes and there are only a few dosage sensitive genes. Smith-Magenis (SMS) and Potocki-Lupski (PTLS) syndromes are associated with a reciprocal microdeletion and microduplication within chromosome 17p11.2. in humans. The dosage sensitive gene responsible for most phenotypes in SMS has been identified: the Retinoic Acid Induced 1 (RAI1). Studies on mouse models and humans suggest that RAI1 is likely the dosage sensitive gene responsible for clinical features in PTLS. In addition, the human RAI1 gene has been implicated in several neurobehavioral traits as spinocerebellar ataxia (SCA2), schizophrenia and non syndromic autism. In this review we discuss the evidence of RAI1 as a dosage sensitive gene, its relationship with different neurobehavioral traits, gene structure and mutations, and what is known about its molecular and cellular function, as a first step in the elucidation of the mechanisms that relate dosage sensitive genes with abnormal neurobehavioral outcomes.

Original languageEnglish
Pages (from-to)607-617
Number of pages11
JournalCurrent Genomics
Volume11
Issue number8
DOIs
StatePublished - Dec 16 2010

Fingerprint

Gene Dosage
Tretinoin
Schizophrenia
Genes
Spinocerebellar Ataxias
Phenotype
Human Genome
Autistic Disorder
Intellectual Disability
Epilepsy
Chromosomes
Mutation

Keywords

  • Copy number variation
  • Dosage sensitive gene
  • Neurobehavioral traits
  • Potocki-lupski syndrome
  • RAI1
  • Smith-magenis syndrome
  • Transcription factor activity

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Retinoic acid induced 1, RAI1 : A dosage sensitive gene related to neurobehavioral alterations including autistic behavior. / Carmona-Mora, Paulina; Walz, Katherina.

In: Current Genomics, Vol. 11, No. 8, 16.12.2010, p. 607-617.

Research output: Contribution to journalArticle

@article{5850a2b95e83445986c45152070b1fab,
title = "Retinoic acid induced 1, RAI1: A dosage sensitive gene related to neurobehavioral alterations including autistic behavior",
abstract = "Genomic structural changes, such as gene Copy Number Variations (CNVs) are extremely abundant in the human genome. An enormous effort is currently ongoing to recognize and catalogue human CNVs and their associations with abnormal phenotypic outcomes. Recently, several reports related neuropsychiatric diseases (i.e. autism spectrum disorders, schizophrenia, mental retardation, behavioral problems, epilepsy) with specific CNV. Moreover, for some conditions, both the deletion and duplication of the same genomic segment are related to the phenotype. Syndromes associated with CNVs (microdeletion and microduplication) have long been known to display specific neurobehavioral traits. It is important to note that not every gene is susceptible to gene dosage changes and there are only a few dosage sensitive genes. Smith-Magenis (SMS) and Potocki-Lupski (PTLS) syndromes are associated with a reciprocal microdeletion and microduplication within chromosome 17p11.2. in humans. The dosage sensitive gene responsible for most phenotypes in SMS has been identified: the Retinoic Acid Induced 1 (RAI1). Studies on mouse models and humans suggest that RAI1 is likely the dosage sensitive gene responsible for clinical features in PTLS. In addition, the human RAI1 gene has been implicated in several neurobehavioral traits as spinocerebellar ataxia (SCA2), schizophrenia and non syndromic autism. In this review we discuss the evidence of RAI1 as a dosage sensitive gene, its relationship with different neurobehavioral traits, gene structure and mutations, and what is known about its molecular and cellular function, as a first step in the elucidation of the mechanisms that relate dosage sensitive genes with abnormal neurobehavioral outcomes.",
keywords = "Copy number variation, Dosage sensitive gene, Neurobehavioral traits, Potocki-lupski syndrome, RAI1, Smith-magenis syndrome, Transcription factor activity",
author = "Paulina Carmona-Mora and Katherina Walz",
year = "2010",
month = "12",
day = "16",
doi = "10.2174/138920210793360952",
language = "English",
volume = "11",
pages = "607--617",
journal = "Current Genomics",
issn = "1389-2029",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Retinoic acid induced 1, RAI1

T2 - A dosage sensitive gene related to neurobehavioral alterations including autistic behavior

AU - Carmona-Mora, Paulina

AU - Walz, Katherina

PY - 2010/12/16

Y1 - 2010/12/16

N2 - Genomic structural changes, such as gene Copy Number Variations (CNVs) are extremely abundant in the human genome. An enormous effort is currently ongoing to recognize and catalogue human CNVs and their associations with abnormal phenotypic outcomes. Recently, several reports related neuropsychiatric diseases (i.e. autism spectrum disorders, schizophrenia, mental retardation, behavioral problems, epilepsy) with specific CNV. Moreover, for some conditions, both the deletion and duplication of the same genomic segment are related to the phenotype. Syndromes associated with CNVs (microdeletion and microduplication) have long been known to display specific neurobehavioral traits. It is important to note that not every gene is susceptible to gene dosage changes and there are only a few dosage sensitive genes. Smith-Magenis (SMS) and Potocki-Lupski (PTLS) syndromes are associated with a reciprocal microdeletion and microduplication within chromosome 17p11.2. in humans. The dosage sensitive gene responsible for most phenotypes in SMS has been identified: the Retinoic Acid Induced 1 (RAI1). Studies on mouse models and humans suggest that RAI1 is likely the dosage sensitive gene responsible for clinical features in PTLS. In addition, the human RAI1 gene has been implicated in several neurobehavioral traits as spinocerebellar ataxia (SCA2), schizophrenia and non syndromic autism. In this review we discuss the evidence of RAI1 as a dosage sensitive gene, its relationship with different neurobehavioral traits, gene structure and mutations, and what is known about its molecular and cellular function, as a first step in the elucidation of the mechanisms that relate dosage sensitive genes with abnormal neurobehavioral outcomes.

AB - Genomic structural changes, such as gene Copy Number Variations (CNVs) are extremely abundant in the human genome. An enormous effort is currently ongoing to recognize and catalogue human CNVs and their associations with abnormal phenotypic outcomes. Recently, several reports related neuropsychiatric diseases (i.e. autism spectrum disorders, schizophrenia, mental retardation, behavioral problems, epilepsy) with specific CNV. Moreover, for some conditions, both the deletion and duplication of the same genomic segment are related to the phenotype. Syndromes associated with CNVs (microdeletion and microduplication) have long been known to display specific neurobehavioral traits. It is important to note that not every gene is susceptible to gene dosage changes and there are only a few dosage sensitive genes. Smith-Magenis (SMS) and Potocki-Lupski (PTLS) syndromes are associated with a reciprocal microdeletion and microduplication within chromosome 17p11.2. in humans. The dosage sensitive gene responsible for most phenotypes in SMS has been identified: the Retinoic Acid Induced 1 (RAI1). Studies on mouse models and humans suggest that RAI1 is likely the dosage sensitive gene responsible for clinical features in PTLS. In addition, the human RAI1 gene has been implicated in several neurobehavioral traits as spinocerebellar ataxia (SCA2), schizophrenia and non syndromic autism. In this review we discuss the evidence of RAI1 as a dosage sensitive gene, its relationship with different neurobehavioral traits, gene structure and mutations, and what is known about its molecular and cellular function, as a first step in the elucidation of the mechanisms that relate dosage sensitive genes with abnormal neurobehavioral outcomes.

KW - Copy number variation

KW - Dosage sensitive gene

KW - Neurobehavioral traits

KW - Potocki-lupski syndrome

KW - RAI1

KW - Smith-magenis syndrome

KW - Transcription factor activity

UR - http://www.scopus.com/inward/record.url?scp=78650001399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650001399&partnerID=8YFLogxK

U2 - 10.2174/138920210793360952

DO - 10.2174/138920210793360952

M3 - Article

C2 - 21629438

AN - SCOPUS:78650001399

VL - 11

SP - 607

EP - 617

JO - Current Genomics

JF - Current Genomics

SN - 1389-2029

IS - 8

ER -